Selective use of SDD has occurred for two decades although its effect on infection with antibiotic-resistant bacteria and death is not clear. In a randomised unblinded trial, Evert de Jonge from Amsterdam's Academic Medical Center, Netherlands, and colleagues randomised 934 patients admitted to a surgical and medical ICU to receive either appropriate antibiotic treatment to facilitate SDD, or standard treatment (the control group).
There were fewer deaths in ICUs (15%) and fewer overall hospital deaths (24%) among SDD patients compared with those given standard treatment (23% and 31%, respectively). Infection with antibiotic-resistant bacteria in ICUs was also lower among SDD patients (16%) than patients given standard treatment (26%).
Evert de Jonge comments: "We conclude that SDD may improve survival of ICU patients and lowers the acquisition of resistant gram-negative aerobic bacteria. In ICUs that have low prevalence of vancomycin-resistant enterococcus and meticillin-resistant S aureus, we advocate the use of SDD in all patients expected to be on mechanical ventilation for at least 2 days or to be in the ICU for at least 3 days."
Contact: Dr Evert de Jonge, c/o Edith Gerritsma or Arthur van Zuylen, Department of Public Relations, Academic Medical Center, PO Box 22660, 1100 DD Amsterdam, The Netherlands; T) +31 20 566 2929; F) +31 20 696 7899; E) wetenschapsvoorlichting@amc.uva.nl
The Lancet